FDA approves first-in-class cancer metabolism drug

The FDA approved Agios' and Celgene's enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells.

Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The IDH enzymes normally metabolize isocitrate into α-ketoglutarate. When they are mutated in cancers, they also convert α-ketoglutarate into 2-hydroxyglutarate, an oncometabolite that causes cell differentiation defects by impairing histone demethylation.

In clinical trials of enasidenib, 23% of treated patients had complete responses or complete responses with partial haematologic recovery lasting a median of 8.2 months. The most common side effects were nausea, vomiting, diarrhoea, elevated bilirubin and decreased appetite. The agency approved the drug with a black box warning noting the risk of differentiation syndrome, a potentially fatal complication that is associated with certain forms of AML.

The FDA also approved a companion diagnostic alongside the drug to detect IDH2 mutations.

Agios discovered and developed the drug in just 8 years. The company started working on IDH2 inhibitors in 2009 and advanced its lead candidate into clinical trials in 2013.

Although the approval highlights the promise of metabolism-modulating anticancer drugs, researchers have struggled to find other therapeutically tractable targets in metabolic pathways (Nat. Rev. Drug Discov. 15, 735–737; 2016). Only a handful of other cancer metabolism candidates have made it into clinical trials. Agios' IDH1 inhibitor is in phase III trials in AML and bile duct cancer. Calithera Biosciences' glutaminase 1 inhibitor CB-839 is in phase II trials for renal cell cancer.

Several of the companies that started in the cancer metabolism space have turned their focus to immunometabolism-modulating drugs that can improve immune cell survival or modify the interactions between cancer cells and immune cells in the microenvironment. Incyte's phase III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor epacadostat, for example, controls tryptophan metabolism to foster immune cell activity.

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. FDA approves first-in-class cancer metabolism drug. Nat Rev Drug Discov 16, 593 (2017). https://doi.org/10.1038/nrd.2017.174

Download citation

Further reading

Search

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing